TetraLogic Pharmaceuticals Corporation
TLOGOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$979
P/E Ratio—
52W High$0.001
52W Low$0.00004
TetraLogic Pharmaceuticals Corporation (TLOG) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TLOG · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2015-12 | 2014-12 | 2013-12 | 2012-12 | 2011-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.05B) | ($0.04B) | ($0.00B) | ($0.02B) | ($0.02B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.00B) | $0.00B | ($0.00B) | $0.00B |
| Net Cash from Operations | ($0.03B) | ($0.03B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.02B) | ($0.07B) | $0.00B | $0.00B | ($0.01B) |
| Sales of Investments | $0.06B | $0.03B | $0.00B | $0.01B | $0.00B |
| Net Cash from Investing | $0.04B | ($0.05B) | ($0.00B) | $0.01B | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | $0.04B | $0.01B | $0.00B | ($0.00B) |
| Net Cash from Financing | $0.00B | $0.04B | $0.06B | $0.00B | $0.01B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.03B) | ($0.03B) | ($0.01B) | ($0.02B) | ($0.02B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more TetraLogic Pharmaceuticals Corporation data
About TetraLogic Pharmaceuticals Corporation (TLOG) Cash Flow Statement
TetraLogic Pharmaceuticals Corporation generated operating cash flow of ($0.03B) and free cash flow of ($0.03B) for 2015 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
TLOG · 4 questionsTetraLogic Pharmaceuticals Corporation generated free cash flow of ($0.03B) for 2015, down 6.3% year-over-year.
TLOG free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10